4D Molecular Therapeutics Inc
General ticker "FDMT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $389.3M
4D Molecular Therapeutics Inc does not follow the US Stock Market performance with the rate: -30.2%.
Estimated limits based on current volatility of 5.2%: low 5.64$, high 6.25$
Factors to consider:
- US accounted for 1.1% of revenue in the fiscal year ended 2022-12-31
- Current price 39.7% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [9.75$, 21.72$]
- 2024-12-30 to 2025-12-30 estimated range: [7.15$, 16.82$]
Financial Metrics affecting the FDMT estimates:
- Negative: Non-GAAP EPS, $ of -2.66 <= 0.10
- Negative: Operating profit margin, % of -84.49 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -10.88 <= 2.35
Short-term FDMT quotes
Long-term FDMT plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $18.04MM | $3.13MM | $20.72MM |
Operating Expenses | $89.37MM | $113.16MM | $133.59MM |
Operating Income | $-71.33MM | $-110.03MM | $-112.87MM |
Non-Operating Income | $0.02MM | $2.54MM | $12.03MM |
R&D Expense | $61.36MM | $80.25MM | $97.10MM |
Income(Loss) | $-71.32MM | $-107.49MM | $-100.84MM |
Profit(Loss) | $-71.32MM | $-107.49MM | $-100.84MM |
Stockholders Equity | $319.11MM | $231.34MM | $307.83MM |
Inventory | $8.50MM | $5.79MM | $0.00MM |
Assets | $353.49MM | $261.85MM | $339.89MM |
Operating Cash Flow | $-69.13MM | $-86.69MM | $-75.79MM |
Capital expenditure | $9.11MM | $11.54MM | $2.77MM |
Investing Cash Flow | $-172.68MM | $-17.05MM | $115.72MM |
Financing Cash Flow | $118.09MM | $3.08MM | $156.83MM |
Earnings Per Share* | $-2.46 | $-3.12 | $-2.58 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.